TAGLN2 and glioma: Since TAGLN2 has been shown to be a poor prognostic biomarker in other cancers and may play a role in glioma progression, we determined whether TAGLN2 expression was associated with overall survival (OS) of patients in both institutional and TCGA glioma cohorts.